Chengdu Tianrui  Xingtong Technology Co., LTD., founded in 2013, is a private high-tech enterprise focusing on microwave, millimeter wave active phased array chip and antenna.

After years of efforts and experience accumulation, Tianriestong has the ability of independent design, research and development, production and service of the whole chain of chip - module - antenna - whole solution - test, and has become one of the most complete enterprises in the industry.

PINS  Medical was founded in 2008, headquartered in Beijing. The company is a high-tech enterprise specializing in the research and development, production and sales of serial neuroregulatory products such as cerebral pacemaker, vagus nerve stimulator, spinal cord stimulator, sacral nerve stimulator, and is committed to providing advanced treatment for patients with Parkinson's disease, epilepsy, pain, urinary incontinence and other functional neurological diseases.

As a component unit of "National Engineering Research Center of Neuroregulation", it has established a collaborative innovation model of "production, study, research and medicine" in close cooperation with Tsinghua University and many clinical hospitals. Since its establishment, the company has undertaken a number of national key research and development programs, national science and technology support programs, Beijing major science and technology special programs and other projects. It has obtained a series of registration certificates of cerebral pacemakers, vagus nerve stimulators, sacral nerve stimulators and spinal nerve stimulators and sold them on the market, breaking the monopoly of American companies in the field of neural regulation products.

Surgerii Robot is a high-tech enterprise committed to completely independent research and development, production and sales of single/porous universal minimally invasive endoscopic surgical robot system. The single-hole endoscopic surgery robot developed by the company is the first similar product to pass the green channel of review and approval of innovative medical devices in China. Currently, it has completed clinical trials in urology surgery and is expected to be approved for market in the first half of 2023. Meanwhile, clinical trials in gynecology, general surgery and thoracic surgery are being carried out simultaneously in Union Medical College Hospital, Ruijin Hospital and Shanghai Chest Hospital. Relying on the innovative design of "dual continuum mechanism", the high-performance deformable surgical arm carried by the company is flexible and accurate, and the comprehensive performance is comparable to the international top single-hole surgical robot, and breaks the foreign technology monopoly for many years in one stroke. At present, the company has obtained 169 authorized patents and established a very high technical barrier.

Huake Precision is a leading company developing intelligent surgery platform for minimally invasive precision treatment in neurosurgery in China. Through a full range of intracranial electrodes, surgical navigation and positioning system, and intracranial laser ablation treatment system, the company covers the whole process solutions of neurosurgery diagnosis, preoperative planning, intraoperative navigation and positioning, real-time monitoring and treatment from top hospitals to primary hospitals, meeting the needs of minimally invasive and craniotomy for a variety of intracranial diseases such as epilepsy, glioma, brain metastasis, and cerebral hemorrhage.
The company adheres to the collaborative development of equipment and consumables. At present, 8 products have obtained the NMPA Class III medical device registration certificate, among which the market share of intracranial electrode reaches 90%, and the domestic market share of neurosurgical robot is the first. Self-developed the first domestic magnetic resonance guided laser ablation system (LITT) will soon be approved for market, and more than ten devices and high-value consumables are under continuous research and development.

Binhui Biopharm is a leading oncolytic drug research and development enterprise in China. The company has the only founding team with successful experience in the research and development of oncolytic virus in China. The founder Liu Binlei is the core original researcher of FDA's first oncolytic virus T-VEC. The company has built a technology platform for oncolytic virus (oHSV2), and the first product developed, OH2 injection, has won the special support of national major new drug creation. It is the only oncolytic virus product with multiple indications and combined PD-(L) 1 in China that has entered the clinical phase II and obtained positive data. Among them, the indications for colorectal cancer and melanoma are about to enter clinical phase III. Based on the leading oHSV2 oncolytic immunotherapy platform, the company not only has a rich pipeline of oncolytic virus products, but also actively develops vector vaccine, recombinant protein vaccine and nucleic acid vaccine, expanding the technology platform covering multiple fields.

Xuanzhu Biology was established in 2002 with a registered capital of 100 million yuan, mainly engaged in the research and development of new molecular solid drugs. Since its establishment, the company has invested more than 2 billion yuan in the field of innovative drugs. At present, the company has formed a complete new drug research and development system, with a professional platform from new drug structure design, evaluation, candidate compound establishment, clinical research, and new drug application. The company has passed the intellectual property management system certification, ISO9001 quality management system certification, in the domestic drug research and development in the leading level, and is committed to building a world-class innovative drug research platform.

Hinova is one of the fastest growing start-up drug discovery and development companies in China. Currently Hinova have one new anti-prostate cancer drug being developed in Phase III of the international multi-center trials, an anti-hyperuricemia and gout drug being developed in Phase I clinical trials in China, as well as several other projects in the stages of IND enabling studies and drug discovery. Hinova endeavor to deliver novel therapies to patients worldwide.

www.hinovapharma.com/

Headquartered in Beijing, CANbridge is a global bio-pharmaceutical company with a mission to accelerate development and commercialization of life-changing specialty healthcare products in China and North Asia.

http://www.canbridgepharma.com/

Geneseeq established in 2008, is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine.Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

https://www.geneseeq.com/

Todaysoft Gene was established in 2000 when the draft of the Human Genome was completed, Todaysoft Gene is a national high-tech enterprise that uses internet and cloud computing technology to achieve the acquisition and application of tumor precise medical clinical big data. Todaysoft Gene is specialized in the research and development of gene sequencing software, clinical gene sequencing, accurate medical data services for tumor and personalized medical services. 

http://www.todaysoft.com.cn/

Cyrano is developing an intranasal therapy using theophylline to treat loss of smell (hyposmia), a condition that affects 14 million in the US caused by a respiratory viral infection or sinusitis and for which there is no existing pharmaceutical treatment. Intranasal theophylline has been shown to be very effective in a pilot clinical trial.

Angioslide Ltd., founded in 2005, is a privately-held medical device company dedicated to provide physicians with cost effective, innovative products for emboli management during vascular interventions. The Company markets the PROTEUS™ device family, the only FDA cleared device that enables physicians to capture and remove embolic particles dislodged at the lesion site in peripheral arteries.

Founded in California, United States, Metronom Health, Inc. is engaged in developing a Continuous Glucose Monitor (“CGM”) based on an optical sensor. The minimal-invasive sensor is designed to enable glucose measurement through interstitial fluid with disruptive accuracy, patient comfort, and self-calibration/monitoring.

Sonendo, Inc., located in California, United States, develops innovative and disruptive technologies to transform traditional endodontic therapy. It changes the standard of care for root canal procedures aimed at making them easier to perform and more comfortable for the patients.

Mitrallign, based in the USA, produces the only direct transcatheter annuloplasty system designed to treat both tricuspid and mitral regurgitation as a market leader.

Vessix is based in California, USA. Vessix Renal denervation is an emerging, minimally-invasive, catheter-based approach to treat uncontrolled hypertension. Vessix had been acquired by Boston Scientific Corporation.

TruTag develops innovative, cost-effective and practical solutions using TruTag microtags made of silicon dioxide, or silica. TruTag was selected by the World Economic Forum as Technology Pioneer (2014). The Forum is committed to improving the state of the world by engaging leaders of society to shape global agendas.

Enife Service, founded in 2008, is the pioneer of China’s third-party supervision and management of food safety. It is a national high-tech enterprise identified by the Ministry of Science and Technology of the PRC, Ministry of Finance of PRC and the State Administration of Taxation. It has obtained the SP License (Type II value-added telecom business certificate) from the Ministry of Industry and Information Technology, the approval of third-party examination institution from China National Accreditation Service for Conformity Assessment, the laboratory approval, and the qualification accreditation from China’s Food inspection and testing institutions.

Venus

Broncus

Sorrento Therapeutics （NASDAQ:SRNE） is a San Diego based, revenue-generating, multi-strategy biopharmaceutical company engaged in discovery, acquisition,and development of therapeutic candidates in oncology. The company focuses in areas of immune-oncology, adoptive cellular immunotherapy, intracellular drug delivery, and refractory/chronic pain. The company has an extensive pipeline of monoclonal and bispecific antibodies for immunotherapy targets, which it generates from its proprietary G-Mab antibody (Ab) discovery platform.

AKDN（837694.OC）

AKDN is a clinical biopharmaceutical company, devoted to the search for a cure for cancer. The company concentrate on developing and commercializing innovation on early tumor detection methodology and targeted cancer therapy pharmaceuticals.

Yingliu Electrome（603308.SH）

Yingliu Electromechanical is one of China’s premier precision steel casting manufacturers.

Mopon（833181.OC）

Founded in 2005, Mopon is a leading provider of mobile e-business infrastructure and operation service in China. It was formally listed on the National Equities Exchange and Quotations in August 2015.

Poly Pharm（300630.SZ）

Hainan Poly Pharm.Co.,Ltd., founded in 1992,is an excellent pharmaceutical manufacturer in China. We are specializing in injections and oral solid formulations. Our mission is good medicine,healthy people.

Sanoculis Ltd. is a medical device start-up company which develops an alternative new surgical procedure for the treatment of Glaucoma. This procedure is expected to be safe, effective and simple to perform and intends to supplement currently available surgical solutions in a multi-billion international market.

Founded in 2012 in Netanya, Israel, Human Extensions Ltd. is a medical device company introducing a disruptive technology for the multi-billion dollar minimally invasive surgery market. The Company is developing an unmediated smart and simple hand held operating system that combines the advantages of robotics with the benefits of affordable hand held instruments, creating a new category in the medical device arena.

was founded in August, 2006 in Nansha, Guangzhou. APT with a registered capital of 319 million RMB, and a total investment is up to 1.5 billion RMB. APT possesses an area of 35,000 square meters as manufacturing plants and research and development base. It aims to accomplish an LED extension with annual capacity of 2 to 2.5 billion; LED chips and module manufacture; and LED light production line, so as to establish an advanced large-scale LED industry chain.